MedTrace Logo

Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation

NCT00375323 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2007-04-20

No results posted yet for this study

Summary

The purpose of the study is to compare the effects of recombinant factor VIIa (NovoSeven) on restoring coagulation activation between patients with hemophilia A and antibodies to factor VIII and normal subjects (controls) by use of an in vivo method.

Conditions

Interventions

DRUG

NovoSeven

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Sabine Eichinger, MD · Medical University of Vienna

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00375323 on ClinicalTrials.gov